We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Effect of Irvingia Gabonensis (Bush Mango)on Parameters Associated With Metabolic Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00645775
Recruitment Status : Completed
First Posted : March 28, 2008
Last Update Posted : March 28, 2008
University of Yaounde
Information provided by:
Gateway Health Alliance

Brief Summary:
The study investigated the use and efficacy of the seeds of African bush mango (Irvingia gabonensis)to control body weight, blood lipids and hormones in overweight and obese people.

Condition or disease Intervention/treatment
Metabolic Syndrome Obesity Dyslipidemia Dietary Supplement: IGOB131

Detailed Description:

To assess the effects of seeds of Irvingia gabonensis on body weight, fasting blood glucose, plasma total and LDL cholesterol in 102 overweight and obese participants.

The study was a 10 week randomized, double blind, placebo controlled design. participants were randomly divided into 2 groups of 51 participants each. Group 1 was the placebo group, while Group 2 was the active group. Each group received 2 daily doses of 125 mg (before meals) of either placebo or Irvingia gabonensis.

Weight as well as fasting blood was taken at baseline and at 4, 8 and 10 weeks. No major detary changes or exercises were suggested during the study period.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 102 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Efficacy of Irvingia Gabonensis (Bush Mango) in the Management of Overweight, Obesity and Metabolic Syndrome in Cameroon.
Study Start Date : November 2006
Primary Completion Date : March 2007
Study Completion Date : April 2007

Arm Intervention/treatment
Placebo Comparator: 1
Compare active to placebo
Dietary Supplement: IGOB131
Comparison of 250 mg per day of Irvingia gabonensis to placebo

Primary Outcome Measures :
  1. Weight change [ Time Frame: 10 weeks ]

Secondary Outcome Measures :
  1. Change in blood lipids and hormone levels [ Time Frame: 10 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   19 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • BMI>26

Exclusion Criteria:

  • Diabetics Pregnant and lactating Participating in any other weight reducing program Smokers

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00645775

Laboratory of Nutrition & Nutritional Biochemistry
Yaounde, Centre, Cameroon, BP812
Sponsors and Collaborators
Gateway Health Alliance
University of Yaounde
Study Director: Julius E Oben, PhD Gateway Health Alliances / University of Yaounde

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Pr. Julius Oben, CSO, Gateway Health Alliances
ClinicalTrials.gov Identifier: NCT00645775     History of Changes
Other Study ID Numbers: GHAIGOB131CT
First Posted: March 28, 2008    Key Record Dates
Last Update Posted: March 28, 2008
Last Verified: August 2006

Keywords provided by Gateway Health Alliance:
Weight loss
Metabolic syndrome

Additional relevant MeSH terms:
Metabolic Syndrome X
Pathologic Processes
Nutrition Disorders
Body Weight
Signs and Symptoms
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases
Lipid Metabolism Disorders